Lindemann K, et al. - In women with “platinum resistant” epithelial ovarian cancer (including fallopian tube and peritoneal cancer), researchers compared response rates and survival of platinum-based chemotherapy vs non-platinum chemotherapy for treatment at first relapse. They found that patients showed a higher response to platinum-chemotherapy at recurrence, vs non-platinum. For subsequent treatment decision-making, the use of a 6-month platinum-free interval as an arbitrary threshold was questioned. To identify potential responders who should be offered platinum re-treatment, biomarkers of platinum-sensitivity are required.